Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
36 hedge funds and large institutions have $194M invested in Evofem Biosciences, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 6 closing their positions.
900% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 1
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
140% more capital invested
Capital invested by funds: $80.7M → $194M (+$113M)
89% more funds holding
Funds holding: 19 → 36 (+17)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$11.5M |
| 2 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$11.3M |
| 3 |
BlackRock
New York
|
+$3.74M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.83M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$362K |
| 2 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$84K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$45K |
| 4 |
IA
Independence Advisors
Wayne,
Pennsylvania
|
-$35K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.63K |
EVFM Hedge Fund Activity: Q2 2019 in Review
36 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q2 2019, worth a combined $194M — up 140% from $80.7M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new EVFM positions and 6 closed out — a net gain of 17 holders — while 10 added to existing stakes and 1 trimmed.
The largest buyer was Invesco, adding an estimated $11.5M. The largest seller was Millennium Management, exiting entirely with an estimated $362K sold.
- 36 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q2 2019, up from 19 in Q1 2019.
- Funds reported $194M of Evofem Biosciences, Inc. Common Stock stock for Q2 2019, up 140% quarter-over-quarter.
- 23 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q2 2019 and 6 closed out, a net change of +17 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q2 2019 was Invesco, an estimated $11.5M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q2 2019 was Millennium Management, an estimated $362K sold.
Based on aggregated 13F filings for Q2 2019.